By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Avanir Pharmaceuticals Inc. et al. v. Par Pharmaceutical Inc. et al.
1:11-cv-00705; filed August 10, 2011 in the District Court of Delaware
• Plaintiffs: Avanir Pharmaceuticals Inc.; Avanir Holding Company; Center for Neurologic Study
• Defendants: Par Pharmaceutical Inc.; Par Pharmaceutical Companies Inc.
Avanir Pharmaceuticals Inc. et al. v. Actavis South Atlantic LLC et al.
1:11-cv-00704; filed August 10, 2011 in the District Court of Delaware
• Plaintiffs: Avanir Pharmaceuticals Inc.; Avanir Holding Company; Center for Neurologic Study
• Defendants: Actavis South Atlantic LLC; Actavis Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 7,659,282 ("Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorder," issued February 9, 2010) and RE38,115 ("Dextromethorphan and an Oxidase Inhibitor for Treating Intractable Conditions," issued May 6, 2003) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Avanir's Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate, used to treat pseudobulbar affect). View the Par complaint here.
Purdue Pharmaceutical Products L.P. et al. v. Hikma (Maple) Ltd. et al.
1:11-cv-00695; filed August 8, 2011 in the District Court of Delaware
• Plaintiffs: Purdue Pharmaceutical Products L.P.; Purdue Pharma L.P.; Purdue Pharma Technologies Inc.
• Defendants: Hikma (Maple) Ltd.; West-Ward Pharmaceuticals Corp.
Infringement of U.S. Patent No. 6,589,960 ("Hydromorphone And Hydrocodone Compositions And Methods For Their Synthesis," issued July 8, 2003) following a Paragraph IV certification as part of Hikma's filing of an ANDA to manufacture a generic version of Purdue Pharma's Dilaudid® (hydromorphone hydrochloride for injection, used to treat moderate to severe pain). View the complaint here.
Braintree Laboratories, Inc. v. Paddock Laboratories, Inc.
3:11-cv-04568; filed August 8, 2011 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,946,149 ("Salt Solution for Colon Cleansing," issued September 20, 2005) following a Paragraph IV certification as part of Paddock's filing of an ANDA to manufacture a generic version of Braintree's Suprep® (sodium sulfate, potassium sulfate and magnesium sulfate osmotic laxative, used for bowel cleansing prior to an adult patient having a colonoscopy procedure). View the complaint here.
ViiV Healthcare UK Ltd. et al. v. Teva Pharmaceuticals USA Inc. et al.
1:11-cv-00688; filed August 5, 2011 in the District Court of Delaware
• Plaintiffs: ViiV Healthcare UK Ltd.; ViiV Healthcare Co.
• Defendants: Teva Pharmaceuticals USA Inc.; Teva Pharmaceutical Industries Ltd.
Infringement of U.S. Patent No. 6,417,191 ("Synergistic Combinations of Zidovudine, 1592U89 and 3TC," issued July 9, 2002) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Viiv's Epzicom® (abacavir sulfate and lamivudine, used to HIV infection in humans). View the complaint here.
Comments